ABSTRACT
El síndrome de Radius-Maumenee (SRM) o hipertensión venosa epiescleral idiopática (HVEI) es un trastorno infrecuente que cursa con una dilatación de los vasos epiesclerales y un aumento de la presión intraocular (PIO). Es un síndrome que constituye un reto diagnóstico y terapéutico para el oftalmólogo. Presentamos un caso en el que, a pesar de hacer un diagnóstico precoz, e intentar planificar un tratamiento orientado a eludir la efusión coroidea, no hemos podido evitar su aparición, teniendo que enfrentarnos a ella en 2 ocasiones con buenos resultados funcionales hasta el momento
Radius-Maumenee syndrome (SRM) or idiopathic episcleral venous hypertension (HVEI) is an uncommon disorder that occurs with a dilation of the episcleral vessels and an increase in intraocular pressure (IOP). It is a syndrome that constitutes a diagnostic and therapeutic challenge for the ophthalmologist. A case is presented in which, despite making an early diagnosis and trying to plan a treatment aimed at avoiding choroidal effusion, its appearance was unavoidable, having to treat it twice with good functional results so far
Subject(s)
Humans , Male , Middle Aged , Glaucoma, Open-Angle/diagnosis , Glaucoma, Open-Angle/therapy , Ocular Hypertension/diagnosis , Ocular Hypertension/therapy , Venous Pressure , Computed Tomography Angiography , Ocular Hypertension/physiopathology , SyndromeABSTRACT
Radius-Maumenee syndrome (SRM) or idiopathic episcleral venous hypertension (HVEI) is an uncommon disorder that occurs with a dilation of the episcleral vessels and an increase in intraocular pressure (IOP). It is a syndrome that constitutes a diagnostic and therapeutic challenge for the ophthalmologist. A case is presented in which, despite making an early diagnosis and trying to plan a treatment aimed at avoiding choroidal effusion, its appearance was unavoidable, having to treat it twice with good functional results so far.
Subject(s)
Hypertension , Sclera/blood supply , Dilatation, Pathologic , Humans , Hypertension/diagnosis , Hypertension/therapy , Intraocular Pressure , Male , Middle Aged , SyndromeABSTRACT
OBJETIVO: Comparar la eficacia y seguridad de bevacizumab como adyuvante a la trabeculectomía frente a mitomicina C. MÉTODO: Se diseñó un estudio comparativo prospectivo no aleatorizado de 180 días de duración con 49 ojos de 45 pacientes: 22 ojos en el grupo de bevacizumab (BVZ) y 27 ojos en el grupo de mitomicina C (MMC). Se estableció como éxito completo: presión intraocular (PIO) menor de 18 mmHg sin fármacos adyuvantes. Se realizaron controles en los días 1, 7, 30, 90 y 180 poscirugía. Se evaluaron: agudeza visual, PIO media en cada una de las visitas, procedimientos adicionales y número de fármacos necesarios para el control de la PIO poscirugía, así como posibles complicaciones posquirúrgicas tanto locales como sistémicas. RESULTADOS: Al final del estudio en la PIO media postoperatoria fue 13,4 ± 3,5 mmHg (rango 8-20) en el grupo del BVZ y de 11,6 ± 2,6 mmHg (rango 7-17) en el grupo de la MMC sin encontrar diferencias estadísticamente significativas (p = 0,08). Se alcanzó el éxito completo al final del seguimiento en un 77,2% (17 de 22) de los pacientes en el grupo de BVZ y en un 96,2% (26 de 27) en el grupo de MMC, siendo esta diferencia estadísticamente significativa (p = 0,024). Un mayor número de pacientes requirió fármacos adicionales para el control de la presión en el grupo de BVZ al final del seguimiento: 0,36 ± 0,72 fármacos frente a 0,03 ± 0,19 fármacos en el de la MMC (p = 0,018). Se encontraron 3 casos de ampollas avasculares en el grupo del BVZ y ninguno en el grupo de MMC. Ningún paciente desarrolló complicaciones derivadas del uso de los medicamentos. CONCLUSIONES: Bevacizumab parece ser un fármaco eficaz y seguro como adyuvante a trabeculectomía, sin embargo la reducción de la presión es algo mayor con la MMC con una menor necesidad de medicación hipotensora. Existe la posibilidad de formación de ampollas avasculares con el uso de bevacizumab intraoperatorio
OBJECTIVE: The objective of this study is to compare the efficacy and safety of bevacizumab versus mitomycin C as an adjuvant anti-scarring agent in Trabeculectomy. METHODS: A prospective, comparative, non-randomized, interventional study was conducted on a case series. A total of 49 eyes of 45 patients with uncontrolled glaucoma were recruited: 22 eyes in the bevacizumab (BVZ) group, and 27 eyes in the mitomycin C (MMC) group. Complete success was defined as intraocular pressure (IOP) less than 18 mmHg without any antiglaucoma medications. Follow-up visits were made on 1, 7, 30, 90 and 180 days after the surgery. Visual acuity, mean IOP, number of antiglaucoma medications and additional procedures to control IOP were recorded at each follow up visit. Local and systemic complications were also noted. RESULTS: At the end of the follow-up there were no significant differences in mean IOP between groups: mean IOP was 13.4 ± 3.5 mmHg (range 8-20) in the BVZ group and 11.6 ± 2.6 mmHg (range 7-17) in the MMC group (P=.08). Complete success was achieved in 77.2% (17 out of 22) in the BVZ group and 96.2% (26 out of 27) in the MMC group, which was a statistically significant difference (P=.024). More patients required antiglaucoma medications to control IOP in the BVZ group at the end of the study: 0.36 ± 0.72 medications versus 0.03 ± 0.19 medications in the MMC group (P=.018). Three patients developed avascular cystic blebs in the BVZ group. None of the patients suffered any ocular or systemic complications related to the use of these agents. CONCLUSION: Bevacizumab could be a safe and effective anti-scarring agent; however IOP reduction appears to be greater with MMC, and also less antiglaucoma medications are needed with this anti-scarring agent. Bevacizumab could favor the formation of avascular cystic blebs
Subject(s)
Humans , Male , Female , Trabeculectomy , Trabeculectomy/methods , Fibrosis/metabolism , Fibrosis/pathology , Anesthesia , Anesthesia/methods , Glaucoma/metabolism , Glaucoma/pathology , Pharmaceutical Preparations/administration & dosage , Pharmaceutical Preparations , Trabeculectomy/adverse effects , Trabeculectomy/instrumentation , Fibrosis/complications , Fibrosis/diagnosis , Anesthesia/standards , Anesthesia , Glaucoma/prevention & control , Glaucoma/surgery , Pharmaceutical Preparations/classification , Pharmaceutical Preparations/supply & distributionABSTRACT
OBJECTIVE: The objective of this study is to compare the efficacy and safety of bevacizumab versus mitomycin C as an adjuvant anti-scarring agent in Trabeculectomy. METHODS: A prospective, comparative, non-randomized, interventional study was conducted on a case series. A total of 49 eyes of 45 patients with uncontrolled glaucoma were recruited: 22 eyes in the bevacizumab (BVZ) group, and 27 eyes in the mitomycin C (MMC) group. Complete success was defined as intraocular pressure (IOP) less than 18 mmHg without any antiglaucoma medications. Follow-up visits were made on 1, 7, 30, 90 and 180 days after the surgery. Visual acuity, mean IOP, number of antiglaucoma medications and additional procedures to control IOP were recorded at each follow up visit. Local and systemic complications were also noted. RESULTS: At the end of the follow-up there were no significant differences in mean IOP between groups: mean IOP was 13.4 ± 3.5mmHg (range 8-20) in the BVZ group and 11.6 ± 2.6 mmHg (range 7-17) in the MMC group (P=.08). Complete success was achieved in 77.2% (17 out of 22) in the BVZ group and 96.2% (26 out of 27) in the MMC group, which was a statistically significant difference (P=.024). More patients required antiglaucoma medications to control IOP in the BVZ group at the end of the study: 0.36 ± 0.72 medications versus 0.03 ± 0.19 medications in the MMC group (P=.018). Three patients developed avascular cystic blebs in the BVZ group. None of the patients suffered any ocular or systemic complications related to the use of these agents. CONCLUSION: Bevacizumab could be a safe and effective anti-scarring agent; however IOP reduction appears to be greater with MMC, and also less antiglaucoma medications are needed with this anti-scarring agent. Bevacizumab could favor the formation of avascular cystic blebs.
Subject(s)
Bevacizumab/therapeutic use , Glaucoma/therapy , Mitomycin/therapeutic use , Trabeculectomy , Aged , Bevacizumab/adverse effects , Chemotherapy, Adjuvant , Combined Modality Therapy , Female , Humans , Male , Mitomycin/adverse effects , Prospective Studies , Treatment OutcomeABSTRACT
Propósito: Describir una serie de casos con glaucoma neovascular que fueron tratados con bevacizumab intracamerular previo a la cirugía filtrante. Diseño: Descriptivo, retrospectivo, tipo serie de casos. Métodos: Cinco ojos de cinco pacientes con glaucoma neovascular de cualquier causa candidatos a cirugía filtrante recibieron previamente una inyección de bevacizumab (1,25mg/0,05ml) intracamerular como tratamiento de la neovascularización angular. Se describen los resultados observados a la semana y a las 4 semanas poscirugía. Resultados: Bevacizumab produjo una regresión importante de los neovasos y de la presión intraocular. Se detectó un único caso de sangrado postoperatorio. Conclusiones: Bevacizumab intracamerular previo a cirugía filtrante de glaucoma disminuyó la neovascularización del segmento anterior y la presión intraocular a las 4 semanas de su administración y resultó eficaz en impedir el sangrado intra- y postoperatorio. También constituye una prometedora vía de investigación para prevenir las complicaciones quirúrgicas(AU)
Purpose: To describe a case series of neovascular glaucoma treated with intracameral bevacizumab prior to filtering surgery. Design: Descriptive, retrospective case series. Methods: Five eyes of 5 patients with neovascular glaucoma due to any cause candidates to filtering surgery who had previously received an injection of intracameral bevacizumab (1.25mg/0.05ml) as treatment for neovascularization of anterior chamber. Results observed one week and 4 weeks postsurgery are reported. Results: Bevacizumab produced regression of the angle neovascularization and the intraocular pressure. Only one case of postoperative bleeding was detected. Conclusions: Intracameral bevacizumab prior to filtering surgery of neovascular glaucoma diminished the neovascularization and intraocular pressure after 4 weeks of its administration and was effective in preventing intraoperative and postoperative bleeding. It also constitutes a promising way of investigation to prevent surgical complications(AU)
Subject(s)
Humans , Glaucoma, Neovascular/surgery , /methods , Antibodies, Monoclonal/administration & dosage , Retrospective Studies , Intravitreal InjectionsABSTRACT
PURPOSE: To describe a case series of neovascular glaucoma treated with intracameral bevacizumab prior to filtering surgery. DESIGN: Descriptive, retrospective case series. METHODS: Five eyes of 5 patients with neovascular glaucoma due to any cause candidates to filtering surgery who had previously received an injection of intracameral bevacizumab (1.25 mg/0.05 ml) as treatment for neovascularization of anterior chamber. Results observed one week and 4 weeks postsurgery are reported. RESULTS: Bevacizumab produced regression of the angle neovascularization and the intraocular pressure. Only one case of postoperative bleeding was detected. CONCLUSIONS: Intracameral bevacizumab prior to filtering surgery of neovascular glaucoma diminished the neovascularization and intraocular pressure after 4 weeks of its administration and was effective in preventing intraoperative and postoperative bleeding. It also constitutes a promising way of investigation to prevent surgical complications.
